HF
KTTA icon

HRT Financial’s Pasithea Therapeutics KTTA Stock Holding History

HRT Financial’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,896
Closed -$7K – 3624
2025
Q3 		$7K Buy
+10,896
New +$7.97K ﹤0.01% 2757
2023
Q3 		– Sell
-2,057
Closed -$20K – 2776
2023
Q2 		$20K Buy
+2,057
New +$16.6K ﹤0.01% 2100
2022
Q1 		– Sell
-637
Closed -$22K – 3489
2021
Q4 		$22K Buy
+637
New +$33.1K ﹤0.01% 2939

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

HRT Financial's KTTA Position: Q4 2025 in Review

HRT Financial sold out of Pasithea Therapeutics (KTTA) in Q4 2025, closing a stake of 10,896 shares — an estimated $7K sold.

HRT Financial first reported a position in KTTA in Q4 2021 and held it in 3 quarters. The position peaked at $22K in Q4 2021. 26 funds tracked by Wall St. Rank hold KTTA as of Q4 2025.

  • HRT Financial reported no remaining Pasithea Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 10,896 Pasithea Therapeutics shares in Q4 2025, an estimated $7K.
  • HRT Financial first reported a position in Pasithea Therapeutics in Q4 2021 and held it in 3 quarters.
  • HRT Financial's Pasithea Therapeutics position peaked at $22K in Q4 2021.
  • 26 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.